Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
McKinsey
Medtronic
Johnson and Johnson
Colorcon

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,255,067

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,255,067
Title: cDNA encoding peptidyl-glycine alpha-amidating monooxygenase (PAM)
Abstract:The sequence of bovine PAM is taught as well as new forms of PAM not known before. One new form is membrane bound and provides the basis of methods for alpha-amidating inactive precursors of peptide hormones.
Inventor(s): Keutmann; Henry T. (Concord, MA), Schofield; Peter (Heidelberg, DE), Rodriguez; Henry (Belmont, CA), Eipper; Betty (Baltimore, MD), Mains; Richard (Baltimore, MD)
Assignee: The Johns Hopkins University (Baltimore, MD)
Application Number:07/096,447
Patent Claims:1. A recombinant DNA molecule which encodes a bovine peptidyl-glycine alpha-amidating monooxygenase (PAM) enzyme.

2. A DNA vector which encodes a bovine PAM enzyme.

3. A DNA vector of claim 2 wherein the PAM enzyme coding sequence is free of introns.

4. The DNA vector of claim 2 wherein the PAM enzyme is PAM-A.

5. The DNA vector of claim 2 wherein the PAM enzyme is PAM-B.

6. The DNA vector of claim 2 comprising the coding sequence of a pro-peptide of PAM.

7. A DNA vector which encodes a bovine PAM enzyme, said PAM enzyme comprising a membrane spanning domain.

8. A DNA vector which encodes a PAM enzyme, said vector comprising the coding sequence for the primary translation product of full length bovine PAM mRNA.

9. A method of producing a bovine PAM enzyme comprising:

providing cultured cells which replicate and express an intron-free DNA sequence encoding a bovine PAM enzyme;

growing said cultured cells; and

recovering the PAM produced form said cultured cells.

10. The method of claim 9 wherein the PAM produced is selected from the group consisting of PAM-A, PAM-B, beta-galactosidase-PAM fusion proteins and the primary translation product of full length PAM mRNA.

11. The method of claim 9 wherein the cultured cells are prokaryotic.

12. The method of claim 9 wherein the cultured cells are eukaryotic.

13. A method of producing a bovine PAM enzyme comprising:

providing cultured cells which replicate and express an intron-free DNA sequence encoding a bovine PAM enzyme, wherein said intron-free DNA sequence comprises a coding sequence for a membrane spanning domain;

growing said cultured cells; and

recovering the PAM produced form said cultured cells.

14. A method of producing a bovine PAM enzyme comprising:

providing cultured cells which replicate and express an intron-free DNA sequence encoding a bovine PAM enzyme, wherein said intron-free DNA sequence comprises a coding sequence for the primary translation product of full length bovine PAM mRNA;

growing said cultured cells; and

recovering the PAM produced form said cultured cells.

15. An in vitro method of activating a peptide hormone precursor to a mature hormone having an alpha-amide group on the C-terminal amino acid residue comprising:

providing a peptide hormone precursor having a glycine residue on the C-terminal side of the C-terminal amino acid residue of the mature hormone; and

contacting said peptide hormone precursor with a membrane preparation having PAM activity due to a bovine PAM enzyme to form an alpha-amidated derivative of the peptide.

16. The method of claim 15 wherein the membrane preparation is prepared from cultured cells which replicate and express the coding sequence of the primary translation product of full length PAM mRNA.

17. The method of claim 15 wherein the membrane preparation is prepared by incorporating a PAM enzyme having a membrane spanning domain into synthetic membranes.

18. The method of claim 15 wherein the membrane preparation is prepared from cultured cells which replicate and express an intron-free DNA sequence of a PAM enzyme.

19. A bovine PAM protein, including a membrane spanning domain and being substantially free of proteins which do not have PAM activity.

20. Culture cells which have been transformed with a vector which encodes a bovine PAM enzyme.

21. The cultured cells of claim 20 which have been transformed with an intron-free DNA sequence of a PAM enzyme.

22. The cells of claim 20 which are prokaryotic.

23. The cells of claim 20 which are yeast cells.

24. The cells of claim 20 which are mammalian.

25. The cells of claim 20 which are avian.

26. Cultured cells which have been transformed with a vector which encodes a bovine PAM enzyme, wherein the PAM enzyme includes a membrane spanning domain.

27. A method of producing a bovine PAM enzyme comprising:

providing cultured cells which replicate and express and intron-free DNA sequence encoding a bovine PAM enzyme;

growing said cultured cells in a culture medium; and

recovering the PAM enzyme from the culture medium.

28. A purified protein selected from the group consisting of bovine pre-PAM and bovine prepro-PAM.

Details for Patent 6,255,067

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial The Johns Hopkins University (Baltimore, MD) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial The Johns Hopkins University (Baltimore, MD) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial The Johns Hopkins University (Baltimore, MD) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
McKinsey
Dow
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.